Literature DB >> 23391114

Management of well-differentiated gastrointestinal neuroendocrine tumors metastatic to the liver.

Sam C Wang1, Nicholas Fidelman, Eric K Nakakura.   

Abstract

Neuroendocrine tumors (NETs) can have indolent clinical courses and patients with metastatic disease may live many years after the initial diagnosis. Recent studies have suggested that aggressive treatments may extend survival. In this review, we assess the recent literature regarding management of well-differentiated NETs from the gastrointestinal (GI) tract metastatic to the liver. We focus on studies regarding surgical resection, embolization, or ablation of hepatic lesions. We also present a management algorithm for patients who present with metastatic lesions but the primary lesion cannot be located. Since NETs are rare, all of the available evidence is based on retrospective studies that have limited sample size. As a result, recommendations are offered with caution.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23391114     DOI: 10.1053/j.seminoncol.2012.11.007

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  2 in total

Review 1.  The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review.

Authors:  Timothy L Fitzgerald; Jason Brinkley; Shannon Banks; Nasreen Vohra; Zachary P Englert; Emmanuel E Zervos
Journal:  Langenbecks Arch Surg       Date:  2014-08-23       Impact factor: 3.445

2.  Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Franco Grimaldi; Nicola Fazio; Roberto Attanasio; Andrea Frasoldati; Enrico Papini; Francesco Angelini; Roberto Baldelli; Debora Berretti; Sara Bianchetti; Giancarlo Bizzarri; Marco Caputo; Roberto Castello; Nadia Cremonini; Anna Crescenzi; Maria Vittoria Davì; Angela Valentina D'Elia; Antongiulio Faggiano; Stefano Pizzolitto; Annibale Versari; Michele Zini; Guido Rindi; Kjell Oberg
Journal:  J Endocrinol Invest       Date:  2014-07-20       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.